Tyr200

Site Information
QLHQNQyyDITLPLL SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 465279

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 )
Disease tissue studied:	esophageal cancer ( 3 ) , lung cancer ( 2 ) , non-small cell lung cancer ( 2 )
Relevant cell line - cell type - tissue:	HeLa (cervical) ( 1 ) , Kyse450 (squamous) ( 3 ) , NCI-H2052 (pulmonary) ( 2 )

References
1	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
2	Rikova K (2006) CST Curation Set: 1694; Year: 2006; Biosample/Treatment: cell line, NCI-H2052/serum starved; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
3	Yu J (2006) CST Curation Set: 1394; Year: 2006; Biosample/Treatment: cell line, Kyse450/-; Disease: esophageal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info